Date: 2016-09-26
Type of information: Nomination
Compound:
Company: Navidea Biopharmaceuticals (USA - OH)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 26, 2016, Navidea Biopharmaceuticals announced that its Board of Directors has appointed Michael M. Goldberg , M.D. as President and Chief Executive Officer effective September 22, 2016 . The Board of Directors has also appointed Eric K. Rowinsky M.D ., a Navidea board member since 2010, as Chairman of Navidea's Board, a position previously held by Dr. Goldberg, who will remain a board member.
Michael M. Goldberg , M.D. has been a member of the Navidea Board of Directors since November 2013 , serving as interim Chief Executive Officer from May to October 2014 . Dr. Goldberg is currently a Managing Partner of Montaur Capital Partners . Prior to this role, he served as the Chairman of the Board and Chief Executive Officer of Emisphere Technologies, Inc. , the pioneer in the development of oral delivery technologies for macromolecules. Prior to Emisphere , he served as Vice President in Investment Banking of The First Boston Corporation , where he was a founding member of the Healthcare Banking Group . Dr. Goldberg graduated from the accelerated six year combined BS/MD program from Rensselaer Polytechnic Institute and the Albany Medical College in 1982, and obtained an M.B.A. from the Graduate School of Business, Columbia University , in 1985.
Eric K. Rowinsky , M.D. has extensive research and drug development experience, oncology expertise, corporate strategy and broad scientific and medical knowledge and has served as a director of Navidea since July 2010 . He is currently Executive Chairman and President, of Rgenix, Inc. During his career, Dr. Rowinsky has held executive positions at Stemline Therapeutics, Inc. , Primrose Therapeutics, and ImClone Systems Incorporated . Prior to that, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center's Institute of Drug Development, including Director of the Institute, Director of Clinical Research and SBC Endowed Chair for Early Drug Development, and concurrently served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio . Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine . Dr. Rowinsky is a member of the boards of directors of Biogen Inc. and Fortress Biosciences, Inc. , publicly-held life sciences companies. He is also an Adjunct Professor of Medicine at New York University .
Financial terms:
Latest news:
